Capillary Testing
DeviceTesting Contour Fit BGMS with capillary blood
Other names: Contour Fit BGMS
NCT Number: NCT05647824
Thunder V4 (TV4) is the code name of a blood glucose monitoring system (BGMS) consisting of a new meter and new Contour FIT test strips. This clinical trial will assess the performance (accuracy) of the TV4 meter by lay users enrolled as subjects in the study, and by health care professionals (also called study staff).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Diablo Clinical Research (DCR), Walnut Creek, California, United States
The study will be conducted at three clinical sites and enroll a total of approximately 402 lay users. Ten to fifteen percent (10 - 15%) of the enrolled subjects will be naïve users (naïve to SMBG's and may include people without diabetes). At least twenty percent (20%) of subjects enrolled with diabetes will have Type 1 diabetes. At least 70% of subjects will be younger than age 65. Sites will also enroll subjects of Chinese descent.
This clinical investigation will be conducted within the US.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For example, people who are not eligible are those who work for companies that create or manufacture the following (or a company that is in a partnership with a company that provides such devices): lancing devices, blood glucose monitoring systems, continuous glucose monitoring systems, insulin pens, or systems related to the measurement of HbA1c.
People who are eligible are those who work for companies associated with products such as wound dressings, medications or dietary products.
Testing Contour Fit BGMS with capillary blood
Other names: Contour Fit BGMS
Testing Contour Fit BGMS using blood from alternative site
Other names: Contour Fit BGMS
Testing Contour Fit BGMS with venous blood
Other names: Contour Fit BGMS
Time frame: 4 weeks
Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL
Time frame: 4 weeks
Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL
Time frame: 4 weeks
Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL
Time frame: 4 weeks
Number of results with scores of 3 or higher to statements concerning instructions for use or ease of use. Scores of 3 or greater (on a scale of 0 to 5) are more favorable to usability.
Ascensia Diabetes Care
Industry
User Performance of the TV4 Blood Glucose Monitoring System
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07728162
Diabetes Mellitus, Disease Attributes
Bolu, Turkey (Türkiye)
View Trial Details